Related Experiment Video

Updated: Jun 23, 2026

A Novel in vivo Gene Transfer Technique and in vitro Cell Based Assays for the Study of Bone Loss in Musculoskeletal Disorders
11:47

A Novel in vivo Gene Transfer Technique and in vitro Cell Based Assays for the Study of Bone Loss in Musculoskeletal Disorders

Published on: June 8, 2014

Future therapeutic targets in osteoporosis

Chad Deal1

  • 1Center for Osteoporosis and Metabolic Bone Disease, Department of Rheumatology, Orthopedic and Rheumatology Institute, Cleveland Clinic, Cleveland, Ohio 44195, USA. dealc@ccf.org

Current Opinion in Rheumatology
|May 23, 2009
PubMed
Abstract

Insights

New osteoporosis treatments include novel antiresorptive and anabolic agents. These therapies target pathways affecting bone turnover, offering future advances in osteoporosis drug therapy.

Area of Science:

  • Bone biology and pharmacology
  • Osteoporosis treatment research
  • Drug development for bone diseases

Background:

  • Osteoporosis is a major health concern characterized by low bone mass and microarchitectural deterioration.
  • Current treatments primarily focus on antiresorptive therapies, with limited anabolic options.
  • Understanding bone turnover pathways is crucial for developing effective osteoporosis medications.

Purpose of the Study:

  • To review emerging therapeutic agents for osteoporosis.
  • To discuss the conceptual framework of antiresorptive and anabolic agents.
  • To examine pathways regulating bone turnover and their therapeutic targets.

Main Methods:

  • Literature review of novel osteoporosis drug development.
  • Analysis of agents targeting bone resorption and formation.
  • Examination of molecular pathways involved in bone metabolism.

Main Results:

  • Novel antiresorptive agents like denosumab and odanacatib are in development.
  • Glucagon-like peptide 2 shows potential in preventing bone resorption.
  • Anabolic agents targeting Wnt signaling (sclerostin, Dkk1) and other pathways are under investigation.

Conclusions:

  • Future osteoporosis treatment landscape will include advanced antiresorptive and anabolic drugs.
  • These novel agents target specific molecular pathways to improve bone health.
  • Advances in drug therapy promise improved management of osteoporosis in the coming years.

Related Concept Videos

Osteoclasts in Bone Remodeling01:31

Osteoclasts in Bone Remodeling

Osteoclasts are cells responsible for bone resorption and remodeling. They originate from hematopoietic progenitor cells present in the bone marrow. Numerous progenitor cells fuse to form multinucleated cells, each with 10-20 nuclei. A single osteoclast has a diameter of 150 to 200 µM. These cells have ruffled borders that break down the underlying bone tissue and release minerals such as calcium into the blood in bone resorption. Osteoclasts cling to bones with their ruffled edges during bone...
Bone Remodeling01:40

Bone Remodeling

Bone remodeling is a continuous and balanced process of bone resorption by osteoclasts and bone formation by osteoblasts. In adults, it helps maintain bone mass and calcium homeostasis. While mechanical stress can stimulate turnover as part of the normal maintenance and reparative process, several hormones also regulate bone remodeling.
Hormones and Bone Tissue01:17

Hormones and Bone Tissue

The endocrine system produces and secretes hormones, which interact with the skeletal system. These hormones control bone growth, maintain bone once it is formed, and remodel it.
Hormones That Influence Osteoblasts and/or Maintain the Matrix
Several hormones are necessary for controlling bone growth and maintaining the bone matrix. The pituitary gland secretes growth hormone (GH), which, as its name implies, controls bone growth. This happens in several ways: first, it triggers chondrocyte...
Bone Disorders01:29

Bone Disorders

Aging and its effect on bone remodeling is the most common cause of bone disorders. In young and healthy people, bone deposition and resorption happen at an equal rate to maintain optimal bone health.
Bone deposition is also affected by the levels of sex hormones like estrogen and testosterone that promote osteoblast activity and bone matrix synthesis. When the level of these hormones decreases due to aging, it causes a reduction in bone deposition. As a result, bone resorption by osteoclasts...
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
Bone Remodeling and Repair01:31

Bone Remodeling and Repair

Osteoclasts are cells responsible for bone resorption and remodeling. They originate from hematopoietic progenitor cells present in the bone marrow. Numerous progenitor cells fuse to form multinucleated cells, each with 10-20 nuclei. A single osteoclast has a diameter of 150 to 200 µM. These cells have ruffled borders that break down the underlying bone tissue and release minerals such as calcium into the blood in bone resorption. Osteoclasts cling to bones with their ruffled edges during bone...